ABSTRACT

CRF ANTAGONISTIC QUINO- AND QUINAZOLINES

This invention concerns compounds of formula



(I),

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R^1 is C_{1-6}alkyl, NR^6R^7, OR^6 or SR^7; R^2 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxy or C_{1-6}alkylthio; R^3 is Ar^1 or Het^1; R^4 and R^5 are each independently selected from hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C_{1-6}alkyl)amino; R^6 is hydrogen, C_{1-6}alkyl, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxy or C_{1-6}alkylthio; R^7 is hydrogen, C_{1-8}alkyl, mono- or di(C_{3-6}cyclo-alkyl)methyl, C_{3-6}cycloalkyl, C_{3-6}alkenyl, hydroxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxy-C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; R^6 is C_{1-8}alkyl, mono- or di(C_{3-6}cycloalkyl)-methyl, Ar^2CH_2, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{3-6}alkenyl, thienylmethyl, furanylmethyl, C_{1-6}alkylthioC_{1-6}alkyl, mono- or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)amino, C_{1-6}alkylcarbonylC_{1-6}alkyl; or R^6 and R^7 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkyl; and Ar^1 and Ar^2 are each optionally substituted phenyl; and Het^1 is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).